Evaluating and Managing Major Depression: Linking Assessment Measures and Outcomes in Light of the Black Box Warning

Thomas L. Campbell, MD
Dr. Campbell is the William Rocktaschel Professor and Chair of Family Medicine and the Associate Director of the University of Rochester Medical Center’s Center for Primary Care. Dr. Campbell received his medical degree at Harvard Medical School in 1979. He completed his residency in family medicine and fellowship in family medicine and psychiatry at the University of Rochester in 1982 and 1984, respectively.

Dr. Campbell has published over 100 books, book chapters, original papers, book reviews, newsletters, editorials, and letters. He has also presented at several professional meetings since 1984. Dr. Campbell currently serves on the editorial board for Qualitative Studies on Health and Well-Being, Psychotherapy: Theory, Research, Practice, Training, and the Journal of Family Psychology.

Henry Chung, MD
Dr. Chung is Executive Director for the Student Health Center and Associate Vice President for Student Health at New York University. He is also Clinical Associate Professor of Psychiatry at New York University School of Medicine.

Dr. Chung has a track record of leadership and achievement in strategic planning, community health, disease management and research in both primary care and behavioral health settings. He has performed research and published articles related to the integration of mental health treatment in primary care, especially for racial and ethnic minorities. In this regard, he was the Founder and Project Director of the Asian American Primary Care and Mental Health “Bridge” Program, a nationally recognized model program for primary care and mental health integration for racial and ethnic minorities. He has been widely recognized for this work as a winner of the Bureau of Primary Health Care Models That Work competition in 2000, which selected the Bridge Program for model replication.

Currently, he is leading a groundbreaking Regional College Health Initiative for the Collaborative Care of Depression – “College Breakthrough Series” 2006-2008 funded by the Aetna Foundation and the New York Community Trust. From 2003-2005, he was the Mental Health Research Core Leader at the newly created NYU Center for the Study of Asian American Health where he currently remains a co-Principal Investigator. Since 2003, he has also been Co-Principal Investigator of the National Depression Leadership Initiative which is jointly sponsored by the American Psychiatric Association, American Academy of Family Physicians and the American College of Physicians. He is also a Board Member of the American Psychiatric Foundation of the American Psychiatric Association.

Maria A. Oquendo, MD
Dr. Oquendo is Professor of Clinical Psychiatry at Columbia University and Vice-Chair for Education in the Department of Psychiatry at Columbia University and the New York State Psychiatric Institute (NYSPI). She is also Director of the Clinical Evaluation Core of the Silvio O. Conte Center for the Neurobiology of Mental Disorders at NYSPI. Her areas of expertise include the diagnosis, pharmacologic treatment and neurobiology of Bipolar Disorder and Major Depression, with a special focus on suicidal behavior as well as Cross Cultural Psychiatry.

Dr. Oquendo graduated summa cum laude and Phi Beta Kappa from Tufts University in 1980. She received her MD from the College of Physicians and Surgeons at Columbia University in 1984. She completed her residency in Psychiatry at the Payne Whitney Psychiatric Clinic in the New York Hospital-Cornell Medical Center.

Dr. Oquendo is the principal investigator on a high-risk study of suicide attempters with Bipolar Disorder and on a prospective study of suicidal behavior in patients with affective and psychotic disorders. She is also a co-investigator on four other NIMH-funded research studies examining the neurobiology of suicidal behavior. She is the Co-Principal Investigator on a Developing Center for Interventions to Prevent Suicide. She is the recipient of a grant from the American Foundation for Suicide Prevention for the study of serotonin transporter binding using PET in bipolar suicide attempters, non-attempters, and healthy volunteers.

Dr. Oquendo teaches at Columbia University. Dr. Oquendo is a member of the American Psychiatric Association, the American College of Neuropsychopharmacology, the APA SAMHSA Fellowship and Selection Corresponding Committee, Group for the Advancement of Psychiatry, Association of Women Psychiatrists and the American Board of Psychiatry and Neurology, on which she also functions as an examiner. She is the president-elect of the American Society of Hispanic Psychiatry. She is an associate editor of the American Journal of Psychiatry and serves on the Scientific Advisory Council of the American Foundation for Suicide Prevention. She is a member of the NIMH scientific review committee, Interventions and Treatment of Mood and Anxiety Disorders (ITMA) responsible for providing peer review of applications for federally funded grants. She has authored or co-authored over 150 peer-reviewed articles, chapters and editorials. She is the recipient of several awards including Exemplary Psychiatrist Award from the National Alliance for the Mentally Ill (1993); Award from the National Alliance for the Mentally Ill for Commitment to Multicultural and Underserved Communities (2002); Travel Award from American Foundation for Suicide Prevention (2003); the Marian Butterfield Early Career Psychiatrist Award from the Association of Women Psychiatrists (2004); and the Gerald Klerman Award from the Depression and Bipolar Support Alliance (2005).

Madhukar H. Trivedi, MD, Moderator
Dr. Trivedi is currently a Professor and Chief of the Division of Mood Disorders, Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas. He holds the Betty Jo Hay Distinguished Chair in Mental Health and the Lydia Bryant Professorship in Psychiatric Research. Dr. Trivedi is an established efficacy and effectiveness researcher in the treatment of depression.

Dr. Trivedi has been a principal investigator in multiple clinical trials funded through NIMH and the Texas Department of Mental Health. He has been involved with evidence-based depression guideline development since 1990, when he joined the Depression Guideline Panel of the AHCPR. Dr. Trivedi has been the Director of the Depression Algorithm for TMAP since its inception. Dr. Trivedi has served as the chair of the Depression Work Group of the International Psychopharmacology Algorithm Project and as the scientific content expert for the San Antonio Cochrane Center’s evidence-based, AHCPR-funded efforts to update the Depression Guidelines. Dr. Trivedi spearheaded the rollout of best practices for the treatment of MDD in various MHMR centers across the State of Texas. Dr. Trivedi is also studying the effectiveness of treatments of Depression in Primary Care.

Dr. Trivedi was also the co-principal investigator of the NIMH-funded project entitled, “Sequenced Treatment Alternatives to Relieve Depression” (STAR*D). Dr. Trivedi is currently the co-principal investigator of the Depression Trials Network Combining Medication to Enhance Depression Outcomes (COMED) trial, which focuses on the use of specific antidepressant combinations to increase remission rates by treating a broader spectrum of depressed patients and by capitalizing on additive pharmacological effects. Dr. Trivedi is also principal investigator of three current NIMH grants entitled, “CBASP Augmentation for Treatment of Chronic Depression (REVAMP),” “Treatment with Exercise Augmentation for Depression (TREAD),” and “Computerized Decision Support System for Depression (CDSS-D).”

Dr. Trivedi has mentored multiple psychopharmacology postdoctoral fellows and research track residents over the past many years in the Mood and Anxiety Disorders.

Dr. Trivedi has received numerous awards including the Gerald L. Klerman award from the National Depressive and Manic- Depressive Association Scientific Advisory Board-NDMDA and the Psychiatric Excellence Award from the Texas Society of Psychiatric Physicians-TSPP.

Dr. Trivedi is or has been a member of several institutional review groups of the NIMH. Dr. Trivedi has published over 275 articles and chapters related to the diagnosis and treatment of mood disorders.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all its CE activities. Faculty must disclose to the participants any significant relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Campbell has no financial relationships to disclose in regard to the products and/or services discussed in this activity.

Dr. Chung has disclosed that has received a grant for “College Breakthrough Series—Depression”, supported by Aetna Foundation and New York Community Trust. He serves on the speakers bureau of Jazz Pharmaceuticals and Pfizer Inc.

Dr. Oquendo has no financial relationships to disclose in regard to the products and/or services discussed in this activity.

Dr. Trivedi has disclosed that he receives research support Bristol-Myers Squibb Company, Cephalon, Inc., Corcept Therapeutics, Inc., Cyberonics, Inc., Eli Lilly and Company, Forest Pharmaceuticals, Inc., GlaxoSmithKline, Janssen L.P., Merck & Co., Inc., National Alliance for Research in Schizophrenia and Depression, National Institute of Mental Health, Novartis Pharmaceuticals Corporation, Pfizer Inc., Pharmacia & Upjohn, Inc., Predix Pharmaceuticals, Solvay Pharmaceuticals, Inc., Wyeth-Ayerst Laboratories. He serves as a consultant to Abbott Laboratories, Akzo Nobel (Organon International), AstraZeneca Pharmaceuticals, Bayer Corp., Bristol- Myers Squibb Company, Cephalon, Inc., Cyberonics, Inc., Eli Lilly and Company, Fabre-Kramer Pharmaceuticals, Inc., Forest Pharmaceuticals, Inc., GlaxoSmithKline, Janssen L.P., Johnson & Johnson Pharmaceutical Research & Development, LLC, Meade- Johnson International Inc., Neuronetics Inc., Parke-Davis Pharmaceuticals, Inc., Pfizer Inc., Pharmacia & Upjohn, Inc., Sepracor Inc., Solvay Pharmaceuticals, Inc., VantagePoint Venture Partners, Wyeth-Ayerst Laboratories. Dr. Trivedi is on the speakers bureaus Abdi Brahim, Akzo Nobel (Organon International), Bristol-Myers Squibb Company, Cephalon, Inc., Cyberonics, Inc., Eli Lilly and Company, Forest Pharmaceuticals, Inc., GlaxoSmithKline, Janssen L.P., Pharmacia & Upjohn, Inc., Solvay Pharmaceuticals, Inc., Wyeth-Ayerst Laboratories.

Unlabeled Use Disclosure

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

The joint sponsors, the faculty, and the New York State Office of Mental Health do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Click here to return to the activity details page.

Questions about this CE activity? Call us at 877.CME.PROS (877.263.7767).